MedTrace Logo

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

NCT03108131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-05-28

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.

Conditions

  • Skin Squamous Cell Carcinoma
  • Appendix Adenocarcinoma
  • Rare Lesion
  • Locally Advanced Malignant Neoplasm
  • Locally Advanced Skin Squamous Cell Carcinoma
  • Metastatic Malignant Neoplasm
  • Metastatic Skin Squamous Cell Carcinoma
  • Metastatic Small Intestinal Adenocarcinoma
  • Rare Neoplastic Syndrome
  • Refractory Malignant Neoplasm
  • Stage IV Small Intestinal Adenocarcinoma AJCC v8
  • Unresectable Malignant Neoplasm

Interventions

DRUG

Atezolizumab

Given IV

DRUG

Cobimetinib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Kanwal P Raghav · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-07
Primary Completion
2024-04-02
Completion
2024-04-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108131 on ClinicalTrials.gov